Torrent Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on January 05, 2026.
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Torrent Pharmaceuticals' Securities Transfer and Stakeholders Relationship Committee, at its meeting on January 5, 2026, approved the issuance of secured, rated, listed, redeemable non-convertible debentures (NCDs) aggregating up to ₹12,500 crore. The NCDs will be issued on a private placement basis in one or more tranches, with up to 12,50,000 NCDs of face value ₹1,00,000 each. The NCDs will be listed on the Wholesale Debt Market Segment of NSE, with annual interest payment schedule and a coupon rate to be determined at issuance. The instrument will be secured by a first-ranking exclusive charge over a designated account and specified trademarks of the company, maintaining a minimum security cover of 1.1x. Tenure, allotment date, and maturity date will be communicated at the time of allotment.
This is a significant debt-raising move by Torrent Pharma that could fund expansion, acquisitions, or refinance existing debt without diluting equity shareholders. The large size of up to ₹12,500 crore and the use of brand/trademark assets as collateral are notable; investors should watch for interest cost implications and how the funds are deployed.